对乙酰氨基酚注射液(Ofirmev)在国外的销售情况?Thank you for your continued support during 2012. Last year was a busy and highly productive year for all of us at Cadence as we focused on accelerating the commercial growth of OFIRMEV® (acetaminophen) injection. Our efforts were rewarded with an increase in net product revenue of more than fourfold, from $11.5 million in 2011 to $50.1 million in 2012. We also took steps to strengthen our balance sheet and secure our supply chain, which we believe leave us well-positioned to continue to deliver strong sales growth. 上文提到对乙酰氨基酚注射液,OFIRMEV在2011年上市之后两年的销售额分别为1150万,和5010万美元。查看更多